Lexibulin
Alternative Names: CYT 997Latest Information Update: 02 Oct 2021
At a glance
- Originator Cytopia Limited
- Developer YM BioSciences Australia
- Class Antineoplastics; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glioblastoma; Multiple myeloma; Solid tumours
Most Recent Events
- 08 Feb 2013 YM BioSciences has been acquired by Gilead Sciences
- 07 Nov 2010 Discontinued - Phase-II for Multiple myeloma in Australia (IV)
- 01 Feb 2010 Cytopia Limited has been acquired by YM BioSciences